Literature DB >> 21118800

Expression of fibrosis-related genes in canine chronic hepatitis.

H Kanemoto1, K Ohno, M Sakai, K Nakashima, M Takahashi, Y Fujino, H Tsujimoto.   

Abstract

Molecular regulation of fibrosis in chronic canine hepatitis is poorly understood. The authors employed quantitative polymerase chain reaction (PCR) to determine the expression levels of genes reported to be related to fibrosis in other species (human, mouse, and rat) and to elucidate the relationship of these genes with the degree of fibrosis and the presence or absence of ascites and/or jaundice in dogs with hepatitis. Nine fibrosis-related genes were assayed: PDGFB, PDGFD, MMP2, TIMP1, THBS1, COL1A1, COL3A1, TGFB1, and TGFB2. Liver samples of 15 dogs with chronic hepatitis and 4 healthy control dogs were obtained via laparoscopic biopsy and subjected to histologic and quantitative PCR analyses. The expression of all 9 genes showed significant positive correlation (P<.01, r>.70) with the degree of fibrosis. Furthermore, the expression levels of all genes except TGFB1 were significantly higher (P<.05) in dogs with hepatic failure-related symptoms (ascites/jaundice). Results suggest that these 9 genes are integral to the development of fibrosis in canine chronic hepatitis.
© The Authors 2011

Entities:  

Mesh:

Year:  2010        PMID: 21118800     DOI: 10.1177/0300985810388523

Source DB:  PubMed          Journal:  Vet Pathol        ISSN: 0300-9858            Impact factor:   2.221


  9 in total

1.  The pathogenesis of diclofenac induced immunoallergic hepatitis in a canine model of liver injury.

Authors:  Saravanakumar Selvaraj; Jung-Hwa Oh; Reinhard Spanel; Florian Länger; Hyoung-Yun Han; Eun-Hee Lee; Seokjoo Yoon; Jürgen Borlak
Journal:  Oncotarget       Date:  2017-09-23

2.  A canine liver fibrosis model to develop a therapy for liver cirrhosis using cultured bone marrow-derived cells.

Authors:  Takashi Matsuda; Taro Takami; Ryo Sasaki; Tatsuro Nishimura; Yuki Aibe; Bruno Diaz Paredes; Luiz Fernando Quintanilha; Toshihiko Matsumoto; Tsuyoshi Ishikawa; Naoki Yamamoto; Kenji Tani; Shuji Terai; Yasuho Taura; Isao Sakaida
Journal:  Hepatol Commun       Date:  2017-07-17

3.  Gene expression patterns in the progression of canine copper-associated chronic hepatitis.

Authors:  Karen Dirksen; Bart Spee; Louis C Penning; Ted S G A M van den Ingh; Iwan A Burgener; Adrian L Watson; Marian Groot Koerkamp; Jan Rothuizen; Frank G van Steenbeek; Hille Fieten
Journal:  PLoS One       Date:  2017-05-01       Impact factor: 3.240

4.  Hepatic and Plasma Endothelin-1 in Dogs with Chronic Hepatitis.

Authors:  Y Sakamoto; M Sakai; T Watari
Journal:  J Vet Intern Med       Date:  2017-03-14       Impact factor: 3.333

5.  Liver regeneration therapy through the hepatic artery-infusion of cultured bone marrow cells in a canine liver fibrosis model.

Authors:  Tatsuro Nishimura; Taro Takami; Ryo Sasaki; Yuki Aibe; Takashi Matsuda; Koichi Fujisawa; Toshihiko Matsumoto; Naoki Yamamoto; Kenji Tani; Yasuho Taura; Isao Sakaida
Journal:  PLoS One       Date:  2019-01-23       Impact factor: 3.240

6.  Plasma renin activity and aldosterone concentration in dogs with acquired portosystemic collaterals.

Authors:  Yumi Sakamoto; Manabu Sakai; Keita Sato; Toshihiro Watari
Journal:  J Vet Intern Med       Date:  2019-11-14       Impact factor: 3.333

7.  Up-regulated extracellular matrix components and inflammatory chemokines may impair the regeneration of cholestatic liver.

Authors:  Shuai Zhang; Tao-Sheng Li; Akihiko Soyama; Takayuki Tanaka; Chen Yan; Yusuke Sakai; Masaaki Hidaka; Ayaka Kinoshita; Koji Natsuda; Mio Fujii; Tota Kugiyama; Zhassulan Baimakhanov; Tamotsu Kuroki; Weili Gu; Susumu Eguchi
Journal:  Sci Rep       Date:  2016-05-26       Impact factor: 4.379

8.  Clinico-hemato-biochemical profile of dogs with liver cirrhosis.

Authors:  M A Elhiblu; K Dua; J Mohindroo; S K Mahajan; N K Sood; P S Dhaliwal
Journal:  Vet World       Date:  2015-04-12

Review 9.  Hepatic Fibrosis in Dogs.

Authors:  V M Eulenberg; J A Lidbury
Journal:  J Vet Intern Med       Date:  2017-11-30       Impact factor: 3.333

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.